

New Cardiotoxic Drugs in Anesthesia and ICU

Essay Submitted for Partial Fulfillment
of Master Degree in Anesthesiology

617.967
H-B.

BY

رما لفتا

Heba Bahaa El-Din El-Serwi

Under the Supervision of

Prof. Dr. Farouk Ahmed Sadek

*Professor of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

56 4 65

60/65

Prof. Dr. Mohammed Abdel Khalek Mohammed


*Professor of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*

Dr. Basel Mohammed Nour El-Din

*Lecturer of Anesthesia and Intensive Care
Faculty of Medicine - Ain Shams University*



**Faculty of Medicine
Ain Shams University
*** 1998 *****





بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم الحكيم

صدق الله العظيم





To My Family



Acknowledgment

I thank **God** who helped me a lot during the performance of this work and forever.

I would like to express my deep thanks and sincere gratitude to **Prof. Dr. Farouk Ahmed Sadek**, Professor of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, who gave me the chance to study this subject, and for his help, guidance and patience throughout this work.

I am deeply grateful to **Prof. Dr. Mohammed Abdel Khalek**, Professor of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, for his kind advice, valuable supervision, and great effort throughout this work.

Also, I am deeply grateful to **Dr. Basel Nour El-Din**, Lecturer of Anesthesia and Intensive Care, Faculty of Medicine, Ain Shams University, for his continuing encouragement and great help during the preparation of this work.

Heba Bahaa El-Din El-Serwi



List of Contents

| | PAGE |
|---|-----------------|
| Introduction | 1 – 2 |
| Chapter 1: Physiological Considerations | 3 – 18 |
| Chapter 2: Pathophysiology of Heart Failure | 19 – 22 |
| Chapter 3: Pharmacological Considerations | 23 – 56 |
| Chapter 4: Clinical Uses in Anesthesia and ICU | 57 – 74 |
| Summary | 75 – 78 |
| References | 79 – 102 |
| Arabic Summary | 1 – 4 |



List of Tables

| No. | Table | Page |
|-------------|---|-------------|
| Table (1): | Determinants of relaxation in the intact heart. | 7 |
| Table (2): | Determinants of left ventricular distensibility. | 8 |
| Table (3): | Factors affecting contractility. | 14 |
| Table (4): | Effect of increased HR on cardiac function. | 17 |
| Table (5): | Congestive heart failure versus low output syndrome. | 20 |
| Table (6): | Characteristics of potential causes of low-output syndrome. | 22 |
| Table (7): | Some of the effects of receptor stimulation by catecholamines. | 26 |
| Table (8): | Sympathomimetics. | 27 |
| Table (9): | Summary of receptor activity of dopexamine, dopamine and dobutamine. | 29 |
| Table (10): | Relative potencies of pharmacological effects of dopexamine. | 29 |
| Table (11): | Incidences of the most frequently occurring adverse effects in clinical trials of dopexamine hydrochloride. | 37 |



List of Figures

| No. | Figure | Page |
|--------------|---|-------------|
| Figure (1): | (A) Length-tension diagram for an isolated cardiac muscle. (B) Sarcomere length tension diagram. | 4 |
| Figure (2): | Pressure volume diagram indicating end-diastolic volume, end-systolic volume, stroke volume, and the equation for ejection fraction.. | 6 |
| Figure (3): | Experimental determination of ESPVR. | 16 |
| Figure (4): | Pressure volume loop with changes in ESPVR. | 16 |
| Figure (5): | Excitation-contraction coupling in the human heart. | 24 |
| Figure (6): | Model of actin-myosin and troponin-tropomyosin system. | 25 |
| Figure (7): | Structural formula of dopamine and its analogue dopexamine hydrochloride. | 28 |
| Figure (8): | Metabolism of dopexamine hydrochloride. | 36 |
| Figure (9): | Structural formula of amrinone. | 39 |
| Figure (10): | Structural formula of milrinone. | 39 |
| Figure (11): | Influence of PDE inhibitors I, II, and III on cyclic nucleotide metabolism. | 40 |
| Figure (12): | Schematic representation of the subcellular site of action of PDE III inhibitors. | 41 |
| Figure (13): | Illustration of the cardiac and vascular effects of PDE III inhibition. | 43 |
| Figure (14): | Chemical structural of enoximone | 49 |
| Figure (15): | Thyroid hormone in patients before, during and after cardiac surgery with CPB. | 55 |

